Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a proven benefit in terms of higher response rate, delaying...

Full description

Saved in:
Bibliographic Details
Published in:Drugs
Main Authors: Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, J., McPhelim, J., Mulatero, C., Subramanian, S., Thomas, A., Thatcher, N., Nicolson, M.
Format: Artigo
Language:Inglês
Published: Springer International Publishing 2015
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4532717/
https://ncbi.nlm.nih.gov/pubmed/26187773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-015-0434-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items